Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation

Summary

This non-inferiority study aims at comparing Versa® to the reference enoxaparin (Clexane®, Sanofi-Aventis) in patients with high-risk unstable angina and NSTEMI. The main justification is the search for scientific evidence to prove the Versa® effectiveness for this new therapeutic indication, since it is a product with potential for reducing costs, with effectiveness and safety comparable to the reference drug.

Timeline

Start

2012-07

Primary completion

2013-07

Completion

2013-07

Drugs

Indications